[Effect of a new beta-receptor blockader (LB 46, Visken) on systemic and pulmonary hemodynamics and on coronary blood flow in humans].
D000293:Adolescent; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000605:Amino Alcohols / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D006328:Cardiac Catheterization; D003326:Coronary Circulation / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D008168:Lung / Q000098:blood supply; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption; D011651:Pulmonary Artery; D013565:Sympatholytics / Q000494:pharmacology*; D014655:Vascular Resistance / Q000187:drug effects
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D007211:Indoles; D013565:Sympatholytics
Zur Wirkung eines neuen beta-Rezeptoren-Blockers (LB 46, Visken) auf die Gross- und Kleinkreislaufhämodynamik sowie den Koronarfluss beim Menschen.